NED-170: Non-Clinical and Clinical Data
NED-170 has been tested in a syngeneic mouse model of metastatic colon cancer at Charles River Labs, a leading contract research laboratory. These studies show that in this model the combination of the NED-170 components together performs better than each individual component or specific subsets.
American Society of Clinical Oncology (ASCO) Breakthrough Therapy peer-reviewed poster
NED-170 has also been used by twenty-seven (27) observational cancer patients. These patients were not part of a controlled clinical trial; however, the observational data from these patients points to the potential use of NED-170 across a range of cancer types and stages of disease. Cancer types represented in these case studies include ovarian cancer, breast cancer, non-small cell lung cancer, leiomyosarcoma, head and neck cancer, gastric squamous, colon cancer, PEComa, prostate, and other cancer types.
Although NED Biosystems has not yet run a controlled clinical trial, to date, NED-170 appears to be well-tolerated. None of the twenty-seven patients reported a drug-related safety or tolerability issue leading to suspension or cessation of therapy. Further, none of these patients required the typical ancillary care (e.g., infusions, ER visits) that is necessary for most cancer patients when treated with chemotherapy or biologics. Given the observed safety, signals of drug activity, and improvements in quality of life, NED Biosystems believes there is an opportunity to make a significant impact on the treatment of cancer, and intends to initiate a controlled clinical trial.